Equity Details
Price & Market Data
Price: $10.98
Daily Change: +$0.381 / 3.47%
Daily Range: $10.50 - $11.75
Market Cap: $516,492,576
Daily Volume: 529,200
Performance Metrics
1 Week: 0.28%
1 Month: 48.05%
3 Months: 173.3%
6 Months: 207.2%
1 Year: 406.2%
YTD: 147.8%
About Artiva Biotherapeutics, Inc. (ARTV)
Discover the market dynamics of Artiva Biotherapeutics, Inc. (ARTV). The stock stands at 10.98, with its daily performance showing a change of +$0.381 / 3.47%. Its market cap is valued at 516,492,576. Explore its 6-month (207.2%) and 1-week (0.28%) performance for a quick overview.
Company Details
Employees: 104
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.